[Update] Signal: TrimRx

[Update] Previously covered: 2026-03-26, MRR change: -11.4%

📊 Data Update Notice This content is an updated version covering TrimRx.

• Previous coverage date: 2026-03-26
• MRR change: $298,994 → $264,808 (-11.4%)
• Previous content ID: 360985c7-2fd8-4c68-a311-e2b503cfa825

1. Track / Niche

Telehealth / GLP-1 Weight Loss. TrimRx is a telehealth company specializing in personalized weight loss programs using GLP-1 medications (Semaglutide, Tirzepatide). Licensed medical providers, FDA-registered pharmacies, US-focused. One of the hottest D2C health tech verticals.

2. Benchmark

TrimRx: GLP-1 telehealth weight loss platform. Founded by Cris in November 2024, reaching $264,808 MRR in just 4 months, 809 active subscriptions, cumulative revenue $11.66M. ARPU ~$327/mo, a high-ticket B2C model. Ranked #4 on TrustMRR.

3. Data / Sources

• TrustMRR: MRR $264,808 (#4 ranked), MoM growth 65%, 809 active subscriptions
• Cumulative Revenue: $11,659,765
• ARPU: ~$327/mo ($264,808 / 809 users)
• Traffic.cv: 2.03M monthly visits (+33.79%), avg. duration 2:23, bounce rate 50.70%, domain age 6.72 years
• Traffic Sources: Direct 51.12%, Search 25.73%, Social 10.70%, Referrals 8.44%, Paid 3.85%
• Top Regions: US 92.30% (highly concentrated), Brazil 0.90%, Canada 0.62%
• Keyword CPC: trimrx $14.2, semaglutide $10.95 — extremely high bidding
• Source: TrustMRR

4. Opportunity Analysis

• Market Validation: Very high. $265K MRR in 4 months, $11.66M cumulative revenue, explosive growth
• MRR Fluctuation: Down 11.4% from previous ($299K→$265K), possibly seasonal or competitive pressure
• High ARPU: $327/mo per user — GLP-1 weight loss is a high-ticket vertical
• Traffic Growth: 2.03M visits growing 33.79%, aligned with US GLP-1 demand explosion
• Competition & Regulation: Crowded field (Ro, Hims, Found), FDA policy changes could impact business
• Timing: Very hot vertical but high regulatory risk; best for teams with medical credentials; tech entrepreneurs could build SaaS tools for such companies